Physician profile
Anne Park
NPI 1417650896
$5,736.09
in general payments reported to CMS, 2019-2025
29 companies · $1,968 in 2025
The $1,968 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,488 · 2024: $2,281 · 2025: $1,968.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,736.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,445.95 | 2023-2025 | Epclusa, Livdelzi, Vemlidy |
| Astrazeneca Pharmaceuticals LP | $715.13 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $498.55 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $381.51 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $375.09 | 2023-2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $248.64 | 2024-2025 | |
| Amgen INC. | $240.79 | 2024-2025 | Repatha, Krystexxa, Otezla |
| Corcept Therapeutics | $217.72 | 2024-2025 | Korlym |
| Lilly USA, LLC | $187.45 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Pfizer INC. | $176.25 | 2023-2025 | |
| Novo Nordisk INC | $151.21 | 2024-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $131.92 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Horizon Therapeutics Plc | $124.97 | 2023 | Krystexxa |
| Kci USA, INC. | $114.73 | 2023 | V.A.C. Veraflo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.74 | 2023-2025 | Xifaxan, Trulance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $76.58 | 2025 | |
| Ascensia Diabetes Care US INC. | $74.63 | 2025 | |
| Dexcom, INC. | $70.92 | 2024-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $66.12 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Janssen Pharmaceuticals, INC | $54.05 | 2025 | Spravato |
| Kowa Pharmaceuticals America, INC. | $49.17 | 2025 | Zoryve |
| Daiichi Sankyo INC. | $47.47 | 2024-2025 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.26 | 2024 | Jardiance |
| Radius Health, INC. | $37.87 | 2025 | Tymlos |
| Mannkind Corporation | $28.79 | 2023-2025 | Afrezza |
| Vanda Pharmaceuticals INC. | $28.39 | 2024 | Fanapt |
| Xeris Pharmaceuticals, INC. | $21.26 | 2025 | Gvoke Hypopen |
| Lundbeck LLC | $15.74 | 2024 | Rexulti |
| Mayne Pharma Commercial LLC | $6.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.